Instrument Inactif

Autres langues Quest PharmaTech Inc Toronto S.E.

Actions

QPT

CA74836M1068

Recherche biotechnologique et médicale

Autres langues

31/05	Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2026
30/05	Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt
29/05	Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis
22/12	Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2025
26/09/25	Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2025
27/08/25	Quest PharmaTech Announces Results from AGM
27/06/25	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2025
11/06/25	Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
02/06/25	Quest PharmaTech Provides Corporate Update
28/05/25	Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2025
28/05/25	Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt
23/12/24	Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2024
11/10/24	Quest PharmaTech Announces Results from AGM
23/09/24	Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2024
28/06/24	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024
30/05/24	Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director
30/05/24	Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors
29/05/24	Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2024
29/05/24	Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt
30/01/24	Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes
30/01/24	Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000
30/01/24	Quest Receives Cash Dividend Payment from OncoQuest
24/01/24	Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis
24/01/24	Quest PharmaTech Inc. - Oregovomab Phase III Clinical Study fails futility analysis, Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
23/01/24	Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits